These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10319861)

  • 21. S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p.
    Codlin S; Mole SE
    J Cell Sci; 2009 Apr; 122(Pt 8):1163-73. PubMed ID: 19299465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Batten disease: evaluation of CLN3 mutations on protein localization and function.
    Haskell RE; Carr CJ; Pearce DA; Bennett MJ; Davidson BL
    Hum Mol Genet; 2000 Mar; 9(5):735-44. PubMed ID: 10749980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A murine model for juvenile NCL: gene targeting of mouse Cln3.
    Greene ND; Bernard DL; Taschner PE; Lake BD; de Vos N; Breuning MH; Gardiner RM; Mole SE; Nussbaum RL; Mitchison HM
    Mol Genet Metab; 1999 Apr; 66(4):309-13. PubMed ID: 10191119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
    Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
    Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization and processing of CLN3, the protein associated to Batten disease: where is it and what does it do?
    Pearce DA
    J Neurosci Res; 2000 Jan; 59(1):19-23. PubMed ID: 10658181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
    Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
    Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue expression and subcellular localization of CLN3, the Batten disease protein.
    Margraf LR; Boriack RL; Routheut AA; Cuppen I; Alhilali L; Bennett CJ; Bennett MJ
    Mol Genet Metab; 1999 Apr; 66(4):283-9. PubMed ID: 10191116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between Sdo1p and Btn1p in the Saccharomyces cerevisiae model for Batten disease.
    Vitiello SP; Benedict JW; Padilla-Lopez S; Pearce DA
    Hum Mol Genet; 2010 Mar; 19(5):931-42. PubMed ID: 20015955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A disrupted homologue of the human CLN3 or juvenile neuronal ceroid lipofuscinosis gene in Saccharomyces cerevisiae: a model to study Batten disease.
    Guo WX; Mao C; Obeid LM; Boustany RM
    Cell Mol Neurobiol; 1999 Oct; 19(5):671-80. PubMed ID: 10384264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide signaling is disrupted in the yeast model for Batten disease.
    Osório NS; Carvalho A; Almeida AJ; Padilla-Lopez S; Leão C; Laranjinha J; Ludovico P; Pearce DA; Rodrigues F
    Mol Biol Cell; 2007 Jul; 18(7):2755-67. PubMed ID: 17475770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CLN3 expression is sufficient to restore G1-to-S-phase progression in Saccharomyces cerevisiae mutants defective in translation initiation factor eIF4E.
    Danaie P; Altmann M; Hall MN; Trachsel H; Helliwell SB
    Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):135-41. PubMed ID: 10229668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells.
    Golabek AA; Kida E; Walus M; Kaczmarski W; Michalewski M; Wisniewski KE
    Mol Genet Metab; 2000 Jul; 70(3):203-13. PubMed ID: 10924275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-species homology of the CLN3 gene.
    Taschner PE; de Vos N; Breuning MH
    Neuropediatrics; 1997 Feb; 28(1):18-20. PubMed ID: 9151313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence.
    Mantel I; Brantley MA; Bellmann C; Robson AG; Holder GE; Taylor A; Anderson G; Moore AT
    Klin Monbl Augenheilkd; 2004 May; 221(5):427-30. PubMed ID: 15162299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression studies of CLN3 protein.
    Kaczmarski W; Kida E; Lach A; Rubenstein R; Zhong N; Wisniewski KE
    Neuropediatrics; 1997 Feb; 28(1):33-6. PubMed ID: 9151318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.
    Chattopadhyay S; Pearce DA
    Mol Genet Metab; 2000; 71(1-2):207-11. PubMed ID: 11001812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesylation of Batten disease CLN3 protein.
    Pullarkat RK; Morris GN
    Neuropediatrics; 1997 Feb; 28(1):42-4. PubMed ID: 9151320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Searching for interacting partners of CLN1, CLN2 and Btn1p with the two-hybrid system.
    Cottone CD; Chattopadhyay S; Pearce DA
    Eur J Paediatr Neurol; 2001; 5 Suppl A():95-8. PubMed ID: 11589016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.
    Narayan SB; Pastor JV; Mitchison HM; Bennett MJ
    Brain; 2004 Aug; 127(Pt 8):1748-54. PubMed ID: 15240430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.
    Savukoski M; Klockars T; Holmberg V; Santavuori P; Lander ES; Peltonen L
    Nat Genet; 1998 Jul; 19(3):286-8. PubMed ID: 9662406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.